无铂间期与复发性子宫内膜癌患者接受铂类再治疗或仑伐替尼/帕博利珠单抗治疗的缓解关联:一项真实世界子宫内膜癌分子靶向治疗联盟队列研究
该回顾性队列纳入217例复发性子宫内膜癌患者,按无铂间期(PFI)≤12个月或>12个月分层,比较铂类再治疗与仑伐替尼/帕博利珠单抗的客观缓解率(ORR)。结果显示较长PFI与二线治疗缓解改善相关(PFI>12个月ORR 68% vs ≤12个月47%,p=0.002),但在任一PFI分层内两种方案的ORR相似。
要点
- 217例中146例(67%)接受铂类再治疗,71例(33%)接受仑伐替尼/帕博利珠单抗。
- 全体患者PFI>12个月ORR 68% vs PFI≤12个月47%(p=0.002)。
- 各PFI分层内铂类与仑伐替尼/帕博利珠单抗的ORR相似(PFI≤12个月49% vs 44%,p=0.75;PFI>12个月67% vs 75%,p=0.74)。
核心结论
- 较长PFI与复发性子宫内膜癌患者二线治疗缓解改善相关。
- 尽管真实世界中PFI被用于治疗决策,但在任一给定PFI下,PFI并未能预测两种方案间的缓解差异。
研究设计与样本
- 子宫内膜癌分子靶向治疗(ECMT2)联盟的回顾性分析,纳入217例复发性子宫内膜癌患者。
- 入组条件为一线接受含铂化疗(辅助或首次复发)后,二线再治疗接受铂类或仑伐替尼/帕博利珠单抗。
- PFI定义为末次铂类给药日期至二线治疗开始日期之间的时间,按PFI≤12个月或>12个月分层。
主要发现
- 217例中146例(67%)接受铂类再治疗,71例(33%)接受仑伐替尼/帕博利珠单抗。
- 127例(59%)PFI≤12个月,84例(39%)PFI>12个月。
- 接受铂类治疗者的PFI长于接受仑伐替尼/帕博利珠单抗者(中位PFI 12.9 vs 4.6个月;p < 0.001)。
- 铂类 vs 仑伐替尼/帕博利珠单抗的ORR为58% vs 49%(p = 0.27)。
- 全体患者中,PFI>12个月 vs ≤12个月的ORR为68% vs 47%(p = 0.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to determine the association between platinum-free interval (PFI) and response to retreatment with platinum-based chemotherapy vs lenvatinib/pembrolizumab in patients with recurrent endometrial cancer. METHODS: Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium patients with recurrent disease were included in this retrospective analysis if they received first-line treatment with platinum-based chemotherapy (adjuvant or first recurrence), followed by second-line re-treatment with platinum or lenvatinib/pembrolizumab. PFI was defined as time between date of last platinum to start date of second-line therapy. Patients were stratified according to PFI ≤12 months or > 12 months. Overall response rate (ORR) to second-line treatment was estimated after stratification by PFI. RESULTS: Of 217 patients, 146 (67 %) underwent retreatment with platinum and 71 (33 %) were treated with lenvatinib/pembrolizumab. 127 (59 %) had PFI ≤12 months, and 84 (39 %) patients had PFI >12 months. Patients treated with platinum had longer PFI than those treated with lenvatinib/pembrolizumab (median PFI 12.9 vs 4.6 months; p < 0.001). ORR was 58 % vs 49 % for platinum vs lenvatinib/pembrolizumab (p = 0.27). For all patients, ORR was 68 % vs 47 % with PFI >12 months and ≤ 12 months, respectively (p = 0.002). At each PFI, ORR was similar regardless of treatment with platinum or lenvatinib/pembrolizumab (PFI ≤12 months ORR 49 % vs 44 % respectively, p = 0.75; PFI >12 months ORR 67 % vs 75 % respectively, p = 0.74). CONCLUSION: Longer PFI is associated with improved response to second-line treatment in patients with recurrent endometrial cancer. Despite utilization of PFI for real-world treatment decisions, it was not found to predict response between regimens at any given PFI.
引用
- Haight PJ, Sanchez M, Thomas SM, et al. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2025. PMID: 39985870. doi:10.1016/j.ygyno.2025.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。